膀胱腫瘍患者におけるIgG-FcR+ Tcellの比率について

Abstract

1)膀胱腫瘍16例, 泌尿器科的良性疾患7例と健常人8例につき末梢血中のIgG-FcR+ T cellの比率を検討した.2) IgG-FcR+ T cellの比率の測定はMorettaの方法と新保らの方法で検討したが, 健常人で前者は後者に比し有意に検出率が高かった.膀胱腫瘍患者と泌尿器科的良性疾患患者のIgG-FcR+ T cellの比率はMorettaの方法で測定した.3)膀胱腫瘍のIgG-FcR+ T cellの比率の平均は対照群に比し有意に高値で, 深達度別でもhigh stage群はlow stage群, 泌尿器科的良性疾患患者と健常人に比し有意に高値を示した.4)膀胱腫瘍13例につき, 手術前後のIgG-FcR+ T cellの比率の変動を検討した.low stage群ではIgG-FcR+ T cellの比率が術前高値例は術後3週間目に正常域に達したが, high stage群では術後3週間目正常域に達した例は少なかった

The T-cell bearing Fc receptor (IgG-FcR+ T cell) has been considered as a suppressor or a part of the killer cell, as determined by its function. The population of IgG-FcR+ T cells was determined by Moretta 's method in patients with urinary bladder cancer, urological benign diseases and in normal subjects. The population of IgG-FcR+ T cells in the peripheral lymphocytes of 16 patients with urinary bladder cancer was 20.5 +/- 10.1%, that of 7 patients with urological benign diseases was 9.5 +/- 3.2%, and that of 8 normal subjects was 9.0 +/- 2.1. The population of IgG-FcR+ T cells in the peripheral lymphocytes patients with high stage bladder cancer was significantly higher than that of patients with low stage cancer. In low stage bladder cancer cases, the population of IgG-FcR+ T cells was decreased to the normal range at three weeks after removal of the tumor. But in high stage bladder cancer cases, it was not changed at 3 weeks.